Parthenolide inhibits the growth of non-small cell lung cancer by targeting epidermal growth factor receptor

BACKGROUND: EGFR tyrosine kinase inhibitors (TKIs) have been developed for the treatment of EGFR mutated NSCLC. Parthenolide, a natural product of parthenolide, which belongs to the sesquiterpene lactone family and has a variety of biological and therapeutic activities, including anti-cancer effects...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancer Cell Int
Egile Nagusiak: Li, Xiaoling, Huang, Riming, Li, Mingyue, Zhu, Zheng, Chen, Zhiyan, Cui, Liao, Luo, Hui, Luo, Lianxiang
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2020
Gaiak:
Primary Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7686780/
https://ncbi.nlm.nih.gov/pubmed/33292235
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12935-020-01658-1
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak